Last reviewed · How we verify
TAK-816
TAK-816 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.
TAK-816 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TAK-816 |
|---|---|
| Sponsor | Takeda |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Nav1.5, TAK-816 is expected to reduce the abnormal electrical activity in the heart that can lead to atrial fibrillation. This mechanism is thought to be effective in preventing stroke in patients with atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Increased risk of atrial fibrillation
Key clinical trials
- Phase III Study of Intramuscular TAK-816 in Healthy Infants (PHASE3)
- Study of TAK-816 in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-816 CI brief — competitive landscape report
- TAK-816 updates RSS · CI watch RSS
- Takeda portfolio CI